Scientists have conducted a substudy within a phase 3 UK trial and have reported the safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with licensed seasonal influenza vaccines.
Scientists have conducted a substudy within a phase 3 UK trial and have reported the safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with licensed seasonal influenza vaccines.